<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01429870</url>
  </required_header>
  <id_info>
    <org_study_id>DIPSO</org_study_id>
    <secondary_id>KEK-ZH 2010-0171-5</secondary_id>
    <nct_id>NCT01429870</nct_id>
  </id_info>
  <brief_title>Steroids Added to Dithranol and Narrow Band UVB(Ultraviolet B) (UVBnb) in Psoriasis</brief_title>
  <acronym>DIPSO</acronym>
  <official_title>A Phase IV, Randomized, Double Blind, Placebo Controlled, Single-center Study of the Impact of Topical Steroids on Narrow Band UVB (Ultraviolet B) and Dithranol Combination Treatment of Psoriasis (DIPSO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective(s):

      (i) To assess the effect of adjunctive topical steroids in the combined treatment with UVBnb
      and dithranol on the remission time after therapy till a relapse of psoriasis defined as 50%
      loss of PASI (Psoriasis Area and Severity Index) improvement obtained through the antecedent
      treatment.

      (ii) To assess the impact of adjuvant topical steroids in the combined treatment with UVBnb
      and dithranol on the clearing time of psoriasis lesions under therapy (PASI 75).

        -  Trial with medicinal product
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      (i) To assess the effect of adjunctive topical steroids in the combined treatment with UVBnb
      and dithranol on the remission time after therapy till a relapse of psoriasis defined as 50%
      loss of PASI (Psoriasis Area and Severity Index) improvement obtained through the antecedent
      treatment.

      (ii) To assess the impact of adjuvant topical steroids in the combined treatment with UVBnb
      and dithranol on the clearing time of psoriasis lesions under therapy (PASI 75).

        -  Trial with medicinal product
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Lack of recruitment
  </why_stopped>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse 50% PASI after treatment, time to PASI 75% on treatment</measure>
    <time_frame>2 years</time_frame>
    <description>Relapse 50% PASI after treatment, time to PASI 75% on treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Steroid active treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Triamcinolone acetonide 0.1% in unguentum leniens topically</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>unguentum leniens topically</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Steroid active treatment</intervention_name>
    <description>Triamcinolone in unguentum leniens 0.1%</description>
    <arm_group_label>Steroid active treatment</arm_group_label>
    <arm_group_label>Vehicle</arm_group_label>
    <other_name>Topical triamcinolone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Moderate to severe psoriasis of the chronic-plaque and / or guttata type

        Exclusion criteria:

          -  Participation in a Goeckerman therapy regimen within 6 months previous to the present
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guenther Hofbauer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Division of Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Dermatology Department</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2011</study_first_submitted>
  <study_first_submitted_qc>September 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2011</study_first_posted>
  <last_update_submitted>December 9, 2015</last_update_submitted>
  <last_update_submitted_qc>December 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
    <mesh_term>Anthralin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

